165 related articles for article (PubMed ID: 31799191)
1. A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
De Luca R; Gouyou B; Ongaro T; Villa A; Ziffels B; Sannino A; Buttinoni G; Galeazzi S; Mazzacuva M; Neri D
Front Oncol; 2019; 9():1228. PubMed ID: 31799191
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
[TBL] [Abstract][Full Text] [Related]
4. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
[No Abstract] [Full Text] [Related]
6. An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.
Prodi E; Comacchio C; Gilardoni E; Di Nitto C; Puca E; Neri D; De Luca R
Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37092450
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Ambrosio MR; Di Serio C; Danza G; Rocca BJ; Ginori A; Prudovsky I; Marchionni N; Del Vecchio MT; Tarantini F
Diagn Pathol; 2016 May; 11(1):45. PubMed ID: 27225200
[TBL] [Abstract][Full Text] [Related]
10. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
[TBL] [Abstract][Full Text] [Related]
11. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
13. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Tickoo SK; Alden D; Olgac S; Fine SW; Russo P; Kondagunta GV; Motzer RJ; Reuter VE
J Urol; 2007 Apr; 177(4):1258-63. PubMed ID: 17382701
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
Christ O; Seiter S; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
[TBL] [Abstract][Full Text] [Related]
16. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
[TBL] [Abstract][Full Text] [Related]
19. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
[TBL] [Abstract][Full Text] [Related]
20. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs.
Dubois L; Peeters SG; van Kuijk SJ; Yaromina A; Lieuwes NG; Saraya R; Biemans R; Rami M; Parvathaneni NK; Vullo D; Vooijs M; Supuran CT; Winum JY; Lambin P
Radiother Oncol; 2013 Sep; 108(3):523-8. PubMed ID: 23849171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
